Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
On-demand Anakinra in Colchicine-resistant FMF
NCT06336733Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Familial Mediterranean fever (FMF) comparing ANAKINRA on Demand with Standard of Care (2 arms). Primary endpoint: Mean number of FMF-attacks per month at 6 months. Started Jun 2024; status: recruiting.
02
Drugs
anakinra
03
Conditions
Familial Mediterranean fever (FMF)
Beyond the preview
Go deeper on NCT06336733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06336733.